Relpax (Eletriptan Hydrobromide) Patent Expiration, LOE Window & CMS Spending
Relpax (Eletriptan Hydrobromide) by Viatris: Off-Patent Genericized (AB Competition), 7 AB generics, $7.1M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Viatris |
| FDA Application & Pathway | N021016 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 7 |
| 2024 CMS Total Public Spend | $7.1M |
| 2024 Medicare Part D Spend | $2.8M |
| 2024 Medicaid Spend | $4.3M |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 17.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.